EA202090004A1 - Биспецифические антитела против pd-1 и против tim-3 - Google Patents

Биспецифические антитела против pd-1 и против tim-3

Info

Publication number
EA202090004A1
EA202090004A1 EA202090004A EA202090004A EA202090004A1 EA 202090004 A1 EA202090004 A1 EA 202090004A1 EA 202090004 A EA202090004 A EA 202090004A EA 202090004 A EA202090004 A EA 202090004A EA 202090004 A1 EA202090004 A1 EA 202090004A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tim
cell
bind
variable domain
bspecific
Prior art date
Application number
EA202090004A
Other languages
English (en)
Inventor
Сесилия Анна Вильгельмина Гёин
Ринсе Клостер
Корнелис Адриан Де Крёйф
Паулус Йоханнес Таккен
Марк Тросби
Тон Логтенберг
Original Assignee
Мерус Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерус Н.В. filed Critical Мерус Н.В.
Publication of EA202090004A1 publication Critical patent/EA202090004A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В документе предложены средства и способы препятствования, опосредуемому белком, запрограммированной гибели клеток 1 (PD-1) и белком 3 Т-клеток, содержащим домен иммуноглобулина и домен муцина (TIM-3), ингибированию в PD-1-положительной и/или TIM-3-положительной клетке. Способ может включать приведение указанной клетки в контакт с антителом или его функциональной частью, производным и/или аналогом, содержащими вариабельный домен, который может связываться с внеклеточной частью PD-1, и вариабельный домен, который может связываться с внеклеточной частью TIM-3, тем самым ингибируя опосредуемую PD-1 и/или TIM-3 активность в указанной клетке. В документе также предложены антитела или их варианты, содержащие вариабельный домен, который может связываться с внеклеточной частью PD-1, и вариабельный домен, который может связываться с внеклеточной частью TIM-3.
EA202090004A 2017-07-06 2018-07-06 Биспецифические антитела против pd-1 и против tim-3 EA202090004A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17180061 2017-07-06
PCT/NL2018/050450 WO2019009727A1 (en) 2017-07-06 2018-07-06 ANTI-PD1 ANTI-TIM3 BISPECIFIC ANTIBODIES

Publications (1)

Publication Number Publication Date
EA202090004A1 true EA202090004A1 (ru) 2020-06-18

Family

ID=59366222

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090004A EA202090004A1 (ru) 2017-07-06 2018-07-06 Биспецифические антитела против pd-1 и против tim-3

Country Status (15)

Country Link
US (2) US11753470B2 (ru)
EP (1) EP3649155A1 (ru)
JP (1) JP7422655B2 (ru)
KR (1) KR20200042467A (ru)
CN (1) CN111094348A (ru)
AU (1) AU2018297058B2 (ru)
BR (1) BR112020000227A2 (ru)
CA (1) CA3068932A1 (ru)
EA (1) EA202090004A1 (ru)
IL (2) IL313753A (ru)
MX (1) MX2020000055A (ru)
PH (1) PH12020550013A1 (ru)
SG (1) SG11202000054RA (ru)
TW (1) TW201920657A (ru)
WO (1) WO2019009727A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200037250A (ko) * 2017-07-06 2020-04-08 메뤼스 엔.페. 세포에 의해 발현되는 생물학적 활성을 조절하는 항체
TWI849895B (zh) * 2018-02-09 2024-07-21 日商小野藥品工業股份有限公司 雙特異性抗體
SG11202009036YA (en) * 2018-03-30 2020-10-29 Merus Nv Multivalent antibody
WO2020227431A1 (en) * 2019-05-06 2020-11-12 Brown University Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells
JP2022534674A (ja) 2019-05-09 2022-08-03 メルス ナムローゼ フェンノートシャップ タンパク質を多量体化する変異体ドメイン及びその分離
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
WO2023089083A1 (en) * 2021-11-19 2023-05-25 Merus N.V. Multispecific binding moieties comprising pd-1 and tgf-brii binding domains

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
EP2314629B2 (en) 2002-07-18 2022-11-16 Merus N.V. Recombinant production of mixtures of antibodies
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP2288715B1 (en) 2008-04-11 2014-09-24 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
KR102261586B1 (ko) 2008-06-27 2021-06-08 메뤼스 엔.페. 항체 생산 비-인간 포유동물
CA2802344C (en) * 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
SI2838918T1 (sl) 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za proizvodnjo heterodimernih IG-podobnih molekul
EP2900694B1 (en) 2012-09-27 2018-09-12 Merus N.V. Bispecific igg antibodies as t cell engagers
WO2015130173A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
SG10202008325XA (en) 2015-10-02 2020-09-29 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
EP3356821B1 (en) * 2015-10-02 2019-10-23 H. Hoffnabb-La Roche Ag Cellular based fret assay for the determination of simultaneous binding
BR112018008068A2 (pt) 2015-10-23 2018-11-13 Merus N.V. moléculas de ligação que inibem o crescimento do câncer
AU2016348388B2 (en) 2015-11-03 2023-11-30 Janssen Biotech, Inc. Antibodies specifically binding PD-1 and their uses

Also Published As

Publication number Publication date
US20200216539A1 (en) 2020-07-09
JP7422655B2 (ja) 2024-01-26
SG11202000054RA (en) 2020-02-27
AU2018297058B2 (en) 2021-04-29
TW201920657A (zh) 2019-06-01
US11753470B2 (en) 2023-09-12
WO2019009727A1 (en) 2019-01-10
US20230357407A1 (en) 2023-11-09
EP3649155A1 (en) 2020-05-13
BR112020000227A2 (pt) 2020-09-29
PH12020550013A1 (en) 2020-10-12
WO2019009727A8 (en) 2020-01-30
IL313753A (en) 2024-08-01
IL271832A (en) 2020-02-27
JP2020532281A (ja) 2020-11-12
CA3068932A1 (en) 2019-01-10
KR20200042467A (ko) 2020-04-23
MX2020000055A (es) 2020-08-06
AU2018297058A1 (en) 2020-01-30
CN111094348A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
EA202090004A1 (ru) Биспецифические антитела против pd-1 и против tim-3
EA202090005A1 (ru) Антитела, модулирующие биологическую активность, проявляемую клеткой
SA518390862B1 (ar) Pd-l1 أجسام مضادة ضد
EA201991156A1 (ru) АНТИТЕЛА К Tim-3 ДЛЯ КОМБИНАЦИИ С АНТИТЕЛАМИ К PD-1
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
SA518390903B1 (ar) أجسام مضادة لـ جديدة pd-1
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
BR112019008494A2 (pt) anticorpos para pd-1 e usos dos mesmos
PH12017502222A1 (en) Lag-3-binding molecules and methods of use thereof
MA46113A (fr) Anticorps dirigés contre l'immunoglobuline de lymphocyte t et la protéine 3 de mucine (tim-3)
MY191649A (en) Antibodies to tigit
MX2019013033A (es) Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso.
EA201792221A1 (ru) Антитела против сортилина и способы их применения
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
MD3456346T2 (ro) Molecule de legare la PD-1 și LAG-3 și metode de utilizare a acestora
NZ734256A (en) Use of plinabulin in combination with immune checkpoint inhibitors
EA202090746A1 (ru) Двойные ингибиторы путей tim-3 и pd-1
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
MX2018012939A (es) Moleculas de union especificas para receptor fc gamma humano iia y usos de las mismas.
PH12021550332A1 (en) Anti-cd33 antibodies and methods of use thereof
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
EA201992186A1 (ru) Антитела к par2 и пути их применения
AR109262A1 (es) Anticuerpos contra tim3 y sus usos
EA201990022A1 (ru) Антитела против c5 и их применение